Analysts Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Target Price at $8.17

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) has received an average recommendation of "Buy" from the seven brokerages that are currently covering the company, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $8.17.

TSHA has been the subject of several recent research reports. Citigroup reiterated an "outperform" rating on shares of Taysha Gene Therapies in a report on Thursday, May 29th. JMP Securities lifted their price target on Taysha Gene Therapies from $5.00 to $6.00 and gave the company a "market outperform" rating in a report on Thursday, May 29th. Needham & Company LLC reissued a "buy" rating and issued a $8.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, July 1st. Chardan Capital raised their price objective on shares of Taysha Gene Therapies from $7.00 to $9.00 and gave the company a "buy" rating in a research report on Thursday, May 29th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Monday, April 28th.

Insider Transactions at Taysha Gene Therapies

In other news, major shareholder Paul B. Manning purchased 750,000 shares of the company's stock in a transaction dated Friday, May 30th. The shares were bought at an average price of $2.75 per share, with a total value of $2,062,500.00. Following the completion of the transaction, the insider directly owned 2,841,704 shares in the company, valued at $7,814,686. This trade represents a 35.86% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.78% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Rhumbline Advisers increased its position in Taysha Gene Therapies by 7.0% in the 1st quarter. Rhumbline Advisers now owns 205,462 shares of the company's stock worth $286,000 after buying an additional 13,383 shares during the period. Octagon Capital Advisors LP increased its position in Taysha Gene Therapies by 2.4% during the first quarter. Octagon Capital Advisors LP now owns 10,700,000 shares of the company's stock worth $14,873,000 after acquiring an additional 250,000 shares during the period. Granahan Investment Management LLC raised its stake in Taysha Gene Therapies by 0.3% during the 1st quarter. Granahan Investment Management LLC now owns 1,640,793 shares of the company's stock valued at $2,281,000 after purchasing an additional 4,412 shares during the last quarter. AQR Capital Management LLC raised its stake in Taysha Gene Therapies by 325.6% during the 1st quarter. AQR Capital Management LLC now owns 107,899 shares of the company's stock valued at $150,000 after purchasing an additional 82,545 shares during the last quarter. Finally, ADAR1 Capital Management LLC grew its position in Taysha Gene Therapies by 500.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 1,066,309 shares of the company's stock worth $1,482,000 after purchasing an additional 888,602 shares during the last quarter. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Taysha Gene Therapies Price Performance

Shares of TSHA remained flat at $2.64 during trading hours on Monday. The stock had a trading volume of 4,149,957 shares, compared to its average volume of 2,911,721. The firm has a fifty day moving average of $2.54 and a 200 day moving average of $1.94. The company has a current ratio of 5.35, a quick ratio of 5.35 and a debt-to-equity ratio of 0.77. The company has a market cap of $566.70 million, a price-to-earnings ratio of -7.76 and a beta of 0.97. Taysha Gene Therapies has a one year low of $1.05 and a one year high of $3.31.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). The firm had revenue of $2.30 million for the quarter, compared to analyst estimates of $1.48 million. Taysha Gene Therapies had a negative net margin of 1,201.08% and a negative return on equity of 104.93%. During the same quarter in the prior year, the business earned ($0.10) EPS. As a group, analysts forecast that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.